Redcare Pharmacy Rallies as Berlin Clears the Digital Path for E-Prescriptions

Redcare shares climbed about 10% to EUR 59.40 after gematik extended CardLink for e-prescriptions and Jefferies reiterated its buy rating with a EUR 97 target.

Redcare Pharmacy shares surged to the top of the German market's watchlist on Thursday, climbing roughly 10% to trade at EUR 59.40. The double-digit advance reflects a potent mix of regulatory breakthroughs in the company's home market and fresh analyst backing — though the stock still sits about 34% below its 52-week high of EUR 90.05, set last October.

A Double Vote of Confidence from Germany's Digital Health Infrastructure

At the heart of the renewed optimism is the national IT agency gematik's decision to extend CardLink, the technology that lets Redcare customers redeem electronic prescriptions directly through the company's own app. The extension also covers the product approval of development partner eHealth Experts GmbH, keeping the most important access route for the prescription (Rx) business in Germany on stable footing. Gematik's move answers a clear need for dependable remote authentication solutions while new technical standards are being drafted.

That parallel track is the so-called PoPP specification — Proof of Patient Presence — which is now taking shape. The framework is designed to support the Health ID, the electronic health card, and the forthcoming EUDI Wallet. Analysts flagged the concretization of this technical foundation on Wednesday as a significant signal for the company's long-term growth strategy. Redcare itself welcomed the publication of the preliminary specification about a week earlier, calling it a milestone for the digital e-prescription infrastructure. For online pharmacies, frictionless, fully digital access to e-prescriptions is the single most important strategic growth lever; until now, hurdles in the patient identification process had kept the electronic prescription from reaching its full potential in the mail-order channel.

Jefferies Sticks With Its Bull Case

Analyst sentiment has reinforced the upward move. Jefferies reiterated its buy rating on Redcare in early September, with a price target of EUR 97 that implies substantial upside from current levels. The analysts acknowledged a softer August in terms of active customers and app usage, but noted the company held up markedly better than rival DocMorris.

The endorsement follows a late-August target hike from EUR 83, driven by strong first-half 2026 results in which Redcare beat expectations on growth, customer acquisition, and profitability. Management had already responded to that momentum in July by raising its full-year 2026 guidance: revenue growth of 15% to 17% is now expected, with the German prescription drug segment targeted at EUR 680 million to EUR 720 million.

New Leadership, Accelerating Operations

Investors are also looking ahead to a changing of the guard at the top. Redcare announced in late August that Peter Schmid von Linstow will succeed Olaf Heinrich as CEO on October 1. The handover arrives at a moment when the business is visibly accelerating: German Rx revenue jumped 58% in the second quarter, group revenue rose 20%, the adjusted EBITDA margin improved, and the international business crossed into profitability. Those operational gains, combined with the regulatory tailwinds now materializing around e-prescriptions, form the foundation for the current stock market recovery.

Political Headwinds and a Supportive Public

Not everything on the regulatory front is smooth sailing. At the Apothekertag, Federal Health Minister Carsten Linnemann announced plans to crack down on competitive distortions caused by discounts from foreign providers — though similar attempts at market regulation have repeatedly stumbled over legal hurdles in the past.

Public opinion, by contrast, leans firmly digital. A current forsa survey for Techniker Krankenkasse found that 83% of respondents want e-prescriptions extended to additional remedies, with approval among under-40s exceeding 90%. Redcare generated EUR 2.9 billion in revenue in fiscal 2025, even as brick-and-mortar pharmacies lost ground in that segment.

The market gave the news a warm reception. The stock gained 6.7% to EUR 57.60 at one point in the session, putting it 1.5% above its 200-day moving average — a reading observers took as a sign of short-term stabilization after weeks of weakness.